(IN BRIEF) Fresenius Kabi has launched its denosumab biosimilars Conexxence® and Bomyntra® across Europe following European Commission approval in July 2025 for all indications of their reference medicines Prolia® and Xgeva®. The products target a range of conditions including osteoporosis, … Read the full press release
Posted in Business, Germany, Healthcare, News, Pharma & Biotech, Science, Technology
Tagged Biosimilar Development, biosimilar portfolio, Bomyntra, bone metastases, Conexxence, denosumab biosimilar, Dr. Sang-Jin Pak, EU approvals, European launch, Fresenius Kabi, Fresenius Kabi Advances Biosimilars Access in Europe with New Approvals for Conexxence and Bomyntra, global healthcare, KabiCare, LUMIADE-3 trial, oncology biosimilars, osteoporosis treatment, patient access, Prolia, RANKL inhibitor, skeletal related events, Xgeva
(IN BRIEF) Sandoz has launched Afqlir®, its biosimilar to aflibercept, across Europe following European Commission approval in 2024. Equivalent in efficacy, safety, and pharmacokinetics to Eylea®, Afqlir® provides a lower-cost treatment option for serious retinal diseases such as nAMD, RVO, … Read the full press release
Posted in Business, Healthcare, Marketing, News, Pharma & Biotech, Switzerland
Tagged aflibercept, Afqlir, anti-VEGF market, biologic medicines, biosimilar portfolio, biosimilars, Christophe Delenta, DME, European Commission approval, European Rollout of Afqlir Marks Major Step in Sandoz Expansion Across Anti-VEGF Ophthalmology Market, Eylea, intravitreal injection, mCNV, nAMD, ophthalmology, retinal diseases, RVO, Sandoz, Sustainable Healthcare, vision loss treatment
EuropaWire (EW) is the first truly pan-European and leading press release distribution and newswire service for Europe and the European Union working towards consolidating Europe’s voice on the global newswire and media scene. The newswire service comes with advanced submission forms, flexible pricing and PR budgeting, granular targeting, nearly uncapped reach across countries, markets, verticals, industries, audiences, languages, etc., translation and localisation for greater local PR impact, in-depth distribution reporting, metrics and insights including measured PR reach, reads, engagements, impact, etc., no cap on words, images and multimedia to go along with your release, among others. Your press releases will be seen among the releases of Europe’s biggest and most prominent companies, brands and institutions. Here you can learn more about EuropaWire’s mission, achievements, services, etc.
HOW TO GET STARTED?